Sanofi

DATA AT EASD SUGGESTS BETTER GLYCAEMIC CONTROL POSSIBLE USING INSULIN GLARGINE OR INSULIN GLULISINE IN TYPE 2 DIABETES

15 September 2005 08:55

Studies show impact of enforced titration of Lantus® (insulin glargine) on reducing HbA1C levels, and Apidra® (insulin glulisine) on postprandial glucose control in patients with type 2 diabetes Athens September 14th, 2005: Data presented at the 41st Annual Meeting of the European Association for the Study of Diabetes (EASD), Athens show that a strictly enforced titration schedule with intensiv

Strong growth in 2005 first half adjusted EPS : up 26.1% at 2.22

31 Augusti 2005 09:44

Increase in full year adjusted EPS guidance Positive phase IIb/III results for 6 products

Ny studie visar stora skillnader i överlevnad inom samma klass bröstcancermedicin

18 Augusti 2005 12:10

I dagens nummer av Journal of Clinical Oncology: Ny studie visar stora skillnader i överlevnad inom samma klass bröstcancermedicin I dagens nummer av den internationella tidskriften Journal of Clinical Oncology har resultaten av den första jämförande studie av olika cellgifter publicerats. I studien jämförs två av de vanligaste cellgifterna vid behandling av avancerad bröstcancer, docetaxel

RESOLUTION OF UK PLAVIX® LITIGATION

8 Augusti 2005 13:55

Today sanofi-aventis announced that Aircoat has withdrawn the revocation action by which it had sought to invalidate the sanofi-aventis patent in the UK claiming clopidogrel bisulfate. Aircoats revocation action was originally announced in January 2005. About sanofi-aventis Sanofi-aventis is the worlds 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&

SANOFI-AVENTIS SELLS ITS INTERESTS IN WACKER-CHEMIE

8 Augusti 2005 08:55

- Hoechst AG, a subsidiary of sanofi-aventis, and the Wacker family agreed on the restructuring of the ownership of Wacker-Chemie GmbH.

Allegra-D® 24 hour (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg) Extended Release Tablets now available in the United-States for seasonal allergy sufferers

28 Juli 2005 09:57

Allegra-D® 24 hour (fexofenadine HCl 180 mg/pseudoephedrine HCl 240 mg) Extended Release Tablets now available in the United-States for seasonal allergy sufferers Läs mer http://en.sanofi-aventis.com/index.asp

Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis

25 Juli 2005 16:14

Läs mer på http://en.sanofi-aventis.com/press/p_press.asp

Strong net sales growth in the first half of 2005

19 Juli 2005 09:41

Strong net sales growth in the first half of 2005: 11.0% on a comparable basis. Further increase in market share in the second quarter.

TRANSFER OF COMMERCIAL RIGHTS OF PLAVIX® IN JAPAN TO SANOFI-AVENTIS

5 Juli 2005 10:53

- Sanofi-aventis and Daiichi Pharmaceutical Co., Ltd. announced today the transfer of all commercial rights for Plavix® (clopidogrel) in Japan from Daiichi and a jointly held partnership to sanofi-aventis Japan. The transfer will be implemented in conformity with local regulatory requirements. Given their long-standing partnership, both parties agreed to collaborate in the future in the areas

PANEL OF EXPERTS AGREE THAT BONE MINERAL DENSITY IS NO LONGER ENOUGH

5 Juli 2005 10:43

Understanding the Factors Which Contribute to Bone Strength Geneva, Switzerland, 28 June, 2005 The Alliance for Better Bone Health announced today that according to evidence presented by an international panel of osteoporosis experts, Bone Mineral Density (BMD) testing does not accurately reflect all factors important to bone strength. The panels findings, presented at the Second Joint Meetin

A high proportion of hypertensive patients achieved blood pressure treatment goal with irbesartan-based combination therapy, findings show

21 Juni 2005 10:14

Contact: sanofi-aventis Jean Marc Podvin +33 (0)1 53 77 42 23 Salah Mahyaoui +33 (0)1 53 77 40 31 +33 (0)6 73 68 78 88 Bristol-Myers Squibb Rob Hutchinson +1 609 252 3901 +1 609 271 2704 Recent clinical findings have demonstrated that a large majority of hypertensive patients who failed to achieve blood pressure goal on monotherapy can be helped to attain goal with the angiotensin-I

Lovenox® Patent Trial Update

17 Juni 2005 08:40

On June 15, 2005, the U.S. District Court for the Central District of California granted the Motion for Summary Judgment for inequitable conduct filed by Amphastar Pharmaceuticals, Inc. in the sanofi-aventis Groups suit against Amphastar and Teva Pharmaceuticals USA, Inc. for infringement of US Patent no. 5,389,618 ('618 patent") by their proposed generic versions of Lovenox®. A formal entry o

Nyhetsarkiv